On the recordMarch 28, 2023
I am concerned that the lack of face-to-face meetings may be negatively affecting the FDA's ability to keep pace and retain its scientific and regulatory stature as the gold standard.
Source
congress.govSusan Collins: “I am concerned that the lack of face-to-face meetings may be negatively affecting the FDA's ability to keep pace and…”
Editor's note · Context
Collins expresses concern over the impact of reduced in-person meetings on FDA's effectiveness.
Share
More from Susan Collins
Oct 6, 2026
There’s only one of us on this stage who has always been pro-choice, and that’s me.
Other voices in this conversation
